Prevention of T cell activation by interference of internalized intravenous immunoglobulin (IVIg) with MHC II-dependent native antigen presentation

Clinical Immunology

Volumn 141, Issue 3, 2011, Pages 273-283

  Aubin, Éric ^a,b   Proulx, Dominic Paquin ^a,b   Trépanier, Patrick ^a,b   Lemieux, Réal ^a   Bazin, Renée ^a,b  

^a Héma Québec ^*  (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Autoimmunity; Helper T cell activation; IVIg; Native antigen presentation

Indexed keywords

FC RECEPTOR; HUMAN IMMUNOGLOBULIN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; ENDOSOME; FEMALE; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOGLOBULINS, INTRAVENOUS; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; OVALBUMIN;

EID: 81355161422     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.06.009     Document Type: Article

References (48)

1. Guermonprez P., Valladeau J., Zitvogel L., Thery C., Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 2002, 20:621-667.
2. Jenkins M.K., Khoruts A., Ingulli E., Mueller D.L., McSorley S.J., Reinhardt R.L., Itano A., Pape K.A. In vivo activation of antigen-specific CD4 T cells. Annu. Rev. Immunol. 2001, 19:23-45.
3. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 1996, 8:348-354.
4. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 1997, 15:821-850.
5. Villadangos J.A. Presentation of antigens by MHC class II molecules: getting the most out of them. Mol. Immunol. 2001, 38:329-346.
6. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 2005, 23:975-1028.
7. Rocha N., Neefjes J. MHC class II molecules on the move for successful antigen presentation. EMBO J. 2008, 27:1-5.
8. Charlton B., Lafferty K.J. The Th1/Th2 balance in autoimmunity. Curr. Opin. Immunol. 1995, 7:793-798.
9. Kroemer G., Hirsch F., Gonzalez-Garcia A., Martinez C. Differential involvement of Th1 and Th2 cytokines in autoimmune diseases. Autoimmunity 1996, 24:25-33.
10. + T-cell subsets in autoimmunity. Curr. Opin. Immunol. 1997, 9:872-883.
11. Lafaille J.J. The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev. 1998, 9:139-151.
12. Crane I.J., Forrester J.V. Th1 and Th2 lymphocytes in autoimmune disease. Crit. Rev. Immunol. 2005, 25:75-102.
13. Knezevic-Maramica I., Kruskall M.S. Intravenous immune globulins: an update for clinicians. Transfusion 2003, 43:1460-1480.
14. Lemieux R., Bazin R., Neron S. Therapeutic intravenous immunoglobulins. Mol. Immunol. 2005, 42:839-848.
15. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., Buckley R., Chinen J., El-Gamal Y., Mazer B.D., Nelson R.P., Patel D.D., Secord E., Sorensen R.U., Wasserman R.L., Cunningham-Rundles C. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 2006, 117:S525-S553.
16. Dalakas M.C. Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects. J. Neurol. 2006, 253(Suppl 5):V25-V32.
17. Negi V.S., Elluru S., Siberil S., Graff-Dubois S., Mouthon L., Kazatchkine M.D., Lacroix-Desmazes S., Bayry J., Kaveri S.V. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 2007, 27:233-245.
18. Aubin E., Lemieux R., Bazin R. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 2010, 115:1727-1734.
19. Martin F., Chan A.C. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 2004, 20:517-527.
20. Wolf S.D., Dittel B.N., Hardardottir F., Janeway C.A. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 1996, 184:2271-2278.
21. Li H., Shi F.D., He B., Bakheit M., Wahren B., Berglof A., Sandstedt K., Link H. Experimental autoimmune myasthenia gravis induction in B cell-deficient mice. Int. Immunol. 1998, 10:1359-1365.
22. Malkiel S., Factor S., Diamond B. Autoimmune myocarditis does not require B cells for antigen presentation. J. Immunol. 1999, 163:5265-5268.
23. Hayward S.L., Bautista-Lopez N., Suzuki K., Atrazhev A., Dickie P., Elliott J.F. CD4 T cells play major effector role and CD8 T cells initiating role in spontaneous autoimmune myocarditis of HLA-DQ8 transgenic IAb knockout nonobese diabetic mice. J. Immunol. 2006, 176:7715-7725.
24. Olsson B., Andersson P.O., Jernas M., Jacobsson S., Carlsson B., Carlsson L.M., Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat. Med. 2003, 9:1123-1124.
25. Martin S., Wolf-Eichbaum D., Duinkerken G., Scherbaum W.A., Kolb H., Noordzij J.G., Roep B.O. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med. 2001, 345:1036-1040.
26. Koren H.S., Handwerger B.S., Wunderlich J.R. Identification of macrophage-like characteristics in a cultured murine tumor line. J. Immunol. 1975, 114:894-897.
27. Sartoris S., Scupoli M.T., Scarpellino L., Paiola F., Jotterand-Bellomo M., Tridente G., Accolla R.S. Inducible and constitutive MHC class II gene expression. Distinct tissue-specific genetic controls. J. Immunol. 1990, 145:1960-1967.
28. Zhong G., Reis e Sousa C., Germain R.N. Production, specificity, and functionality of monoclonal antibodies to specific peptide-major histocompatibility complex class II complexes formed by processing of exogenous protein. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13856-13861.
29. Proulx D.Paquin, Aubin E., Lemieux R., Bazin R. Spontaneous internalization of IVIg in activated B cells. Immunol. Lett. 2009, 124:18-26.
30. Drouin M., Cayer M.P., Jung D. Adenovirus 5 and chimeric adenovirus 5/F35 employ distinct B-lymphocyte intracellular trafficking routes that are independent of their cognate cell surface receptor. Virology 2010, 401:305-313.
31. Shimonkevitz R., Colon S., Kappler J.W., Marrack P., Grey H.M. Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J. Immunol. 1984, 133:2067-2074.
32. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
33. Crow A.R., Song S., Freedman J., Helgason C.D., Humphries R.K., Siminovitch K.A., Lazarus A.H. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 2003, 102:558-560.
34. Bruhns P., Samuelsson A., Pollard J.W., Ravetch J.V. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003, 18:573-581.
35. Siragam V., Crow A.R., Brinc D., Song S., Freedman J., Lazarus A.H. Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells. Nat. Med. 2006, 12:688-692.
36. Park-Min K.H., Serbina N.V., Yang W., Ma X., Krystal G., Neel B.G., Nutt S.L., Hu X., Ivashkiv L.B. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007, 26:67-78.
37. Proulx D.Paquin, Aubin E., Lemieux R., Bazin R. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin. Immunol. 2010, 135:422-429.
38. Mukherjee R., Chaturvedi P., Lee-Chan E., Singh B. Exogenous CLIP localizes into endocytic compartment of cells upon internalization: implications for antigen presentation by MHC class II molecules. Mol. Immunol. 2008, 45:2166-2176.
39. Gautam A.M., Glynn P. Competition between foreign and self proteins in antigen presentation. Ovalbumin can inhibit activation of myelin basic protein-specific T cells. J. Immunol. 1990, 144:1177-1180.
40. Larroche C., Chanseaud Y., Garcia de la Pena-Lefebvre P., Mouthon L. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. BioDrugs 2002, 16:47-55.
41. Bayry J., Thirion M., Misra N., Thorenoor N., Delignat S., Lacroix-Desmazes S., Bellon B., Kaveri S., Kazatchkine M.D. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol. Sci. 2003, 24(Suppl 4):S217-S221.
42. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 2008, 26:513-533.
43. Arnson Y., Shoenfeld Y., Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 2009, 42:553-560.
44. Bayry J., Lacroix-Desmazes S., Carbonneil C., Misra N., Donkova V., Pashov A., Chevailler A., Mouthon L., Weill B., Bruneval P., Kazatchkine M.D., Kaveri S.V. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003, 101:758-765.
45. Enk A.H., Angeloni V.L., Udey M.C., Katz S.I. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol. 1993, 151:2390-2398.
46. Caux C., Massacrier C., Vanbervliet B., Barthelemy C., Liu Y.J., Banchereau J. Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Int. Immunol. 1994, 6:1177-1185.
47. De Groot A.S., Moise L., McMurry J.A., Wambre E., Van Overtvelt L., Moingeon P., Scott D.W., Martin W. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008, 112:3303-3311.
48. St-Amour I., Laroche A., Bazin R., Lemieux R. Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins. Clin. Immunol. 2009, 133:52-60.